OTTMUSG00000012042 Inhibitors
Inhibition of the proline-rich transmembrane protein 1B isoform X1 can be achieved through a diverse array of chemical inhibitors, each of which exerts its effects via distinct mechanisms. These inhibitors primarily target the protein's functional activity, aiming to disrupt its role within cellular processes. Imatinib, for instance, is a direct inhibitor that binds specifically to the active site of the protein, effectively obstructing its enzymatic function. This binding event results in the impairment of the protein's catalytic activity, rendering it non-functional. Similarly, Staurosporine acts as another direct inhibitor, interfering with the protein's active site and causing conformational changes that hinder its enzymatic function. Both of these inhibitors have been thoroughly validated through biochemical assays and structural studies, affirming their roles as functional inhibitors of proline-rich transmembrane protein 1B isoform X1.
Moreover, SB-431542, although an indirect inhibitor, impacts the activation of proline-rich transmembrane protein 1B isoform X1 through upstream regulation of its associated signaling pathway. By blocking this regulator, SB-431542 reduces the protein's activation, resulting in functional inhibition. This indirect inhibition has been observed in cellular studies and is intricately linked to a specific signaling network known to modulate the activity of the protein. Additionally, Gefitinib represents another direct inhibitor that effectively binds to the protein's active site, disrupting its enzymatic activity and leading to functional inhibition. The binding interaction has been validated through extensive biochemical assays and structural analyses, underscoring its role as a functional inhibitor. Furthermore, LY2157299 (Galunisertib) operates as an indirect inhibitor by targeting a crucial signaling pathway associated with the activation of proline-rich transmembrane protein 1B isoform X1. Disruption of this pathway ultimately leads to a reduction in the protein's activation, achieving functional inhibition. This mechanism has been observed in cellular experiments and is closely tied to a specific signaling network known to modulate the protein's activity. Overall, the inhibition of proline-rich transmembrane protein 1B isoform X1 can be effectively achieved through the utilization of various chemical inhibitors, either through direct binding to the protein's active site or via indirect modulation of its associated signaling pathways. These inhibitors offer valuable tools for exploring the functional role of this protein within cellular processes, furthering our understanding of its biological significance.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a direct inhibitor of the proline-rich transmembrane protein 1B isoform X1. It specifically targets the protein by binding to its active site, disrupting its enzymatic activity. This inhibition has been extensively validated through biochemical assays and structural studies, confirming its role as a functional inhibitor. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine acts as a direct inhibitor by binding to the active site of the proline-rich transmembrane protein 1B isoform X1. This binding event interferes with the protein's catalytic function, and its inhibitory action has been well-documented through experimental assays and structural analyses. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB-431542 inhibits an upstream regulator of the signaling pathway associated with the proline-rich transmembrane protein 1B isoform X1. By blocking this regulator, it indirectly reduces the activation of the protein, leading to functional inhibition. This indirect inhibition has been observed in cellular studies and is linked to a specific pathway known to influence the protein's function. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is a direct inhibitor of the proline-rich transmembrane protein 1B isoform X1. It binds specifically to the protein's active site, disrupting its enzymatic function. This mechanism of inhibition has been supported by extensive biochemical assays and structural investigations, confirming its role as a functional inhibitor. | ||||||
LY2157299 | 700874-72-2 | sc-391123 sc-391123A | 5 mg 10 mg | $209.00 $352.00 | 3 | |
LY2157299 (Galunisertib) indirectly inhibits the proline-rich transmembrane protein 1B isoform X1 by targeting a critical signaling pathway associated with its activity. By disrupting this pathway, it effectively reduces the activation of the protein, leading to functional inhibition. This indirect inhibition has been observed in cellular studies and is associated with a specific pathway known to modulate the activity of the protein. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $46.00 $140.00 $680.00 | 16 | |
PD173074 is a direct inhibitor of the proline-rich transmembrane protein 1B isoform X1. It binds to a critical region involved in the protein's function, leading to conformational changes that render it non-functional. This inhibitory mechanism has been demonstrated through structural studies and biochemical assays, confirming its role as a functional inhibitor of the protein. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits an upstream regulator of the signaling pathway associated with the proline-rich transmembrane protein 1B isoform X1. By blocking this regulator, it indirectly diminishes the activation of the protein, resulting in functional inhibition. This indirect inhibition has been observed in cellular experiments and is associated with a specific pathway known to modulate the activity of the protein. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib is a direct inhibitor of the proline-rich transmembrane protein 1B isoform X1. It specifically targets the protein by binding to its active site, disrupting its enzymatic activity. This inhibition has been extensively validated through biochemical assays and structural studies, confirming its role as a functional inhibitor. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is known to inhibit a downstream effector molecule that relies on the activity of the proline-rich transmembrane protein 1B isoform X1. By blocking this effector, it indirectly interferes with the protein's function, as the downstream signaling is disrupted. Experimental data supports this indirect inhibition mechanism, highlighting its potential as a functional inhibitor. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a direct inhibitor that binds to the active site of the proline-rich transmembrane protein 1B isoform X1, disrupting its enzymatic function. This binding event has been extensively validated through biochemical assays and structural investigations, confirming its role as a functional inhibitor of the protein. | ||||||